NCT02720627View on ClinicalTrials.gov

An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 28, 2016

Primary Completion Date

March 21, 2018

Study Completion Date

March 21, 2018

Conditions
Acne Vulgaris
Interventions
DRUG

cortexolone 17α-propionate

CB-03-01 cream is a topical steroidal antiandrogen that is being developed for the potential treatment of acne vulgaris, an androgen-dependent skin disorder.

Trial Locations (10)

72916

Site 103, Fort Smith

77030

Site 102, Houston

92037

Site 101, San Diego

Unknown

Site 4814, Częstochowa

Site 4811, Katowice

Site 4813, Krakow

Site 4815, Krakow

Site 4816, Rzeszów

Site 4812, Szczecin

Site 4817, Tarnów

Sponsors

Lead Sponsor

Cassiopea SpA
All Listed Sponsors
lead

Cassiopea SpA

INDUSTRY